Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract

Clinical and Translational Gastroenterology

Volumn 6, Issue , 2015, Pages

  Tsuda, Ayumi ^a   Suda, Wataru ^b   Morita, Hidetoshi ^c   Takanashi, Kageyasu ^b   Takagi, Atsushi ^a   Koga, Yasuhiro ^a   Hattori, Masahira ^b  

^a TOKAI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c AZABU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACTINOMYCES; ADULT; ARTICLE; BACTERIAL COUNT; BACTERIAL OVERGROWTH; BACTEROIDES; BETA DIVERSITY; BIFIDOBACTERIUM; BLAUTIA; CLINICAL ARTICLE; CLOSTRIDIUM; COLLINSELLA; COLON; COLON FLORA; COMMUNITY STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DYSPEPSIA; EUBACTERIUM; FAECALIBACTERIUM; FECES; FECES MICROFLORA; FEMALE; FUSOBACTERIUM; GASTRIC ACID SUPPRESSION; GASTROESOPHAGEAL REFLUX; GEMELLA; GRANULICATELLA; HUMAN; MALE; MICROBIAL COMMUNITY; MOUTH CAVITY; MOUTH FLORA; NEISSERIA; NONHUMAN; PARABACTEROIDES; POPULATION ABUNDANCE; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ROTHIA; RUMINOCOCCUS; SALIVA; SPECIES RICHNESS; STOMACH; STOMACH JUICE; STOMACH PARAMETERS; STREPTOCOCCUS; VEILLONELLA;

EID: 84931261859     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2015.20     Document Type: Article

References (26)

1. Ruddell WSJ, Axon ATR, Findlay JM et al. Effect of cimetidine on the gastric bacterial flora. Lancet 1980; 1: 672-674.
2. Delgado S, Cabrera-Rubio R, Mira A et al. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb Ecol 2013; 65: 763-772.
3. Sandra Dial M. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009; 104: S10-S16.
4. Williams C, McColl KEL. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006;23:3-10.
5. Li J, Jia H, Cai X et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol 2014; 32: 834-841.
6. Simon-Soro A, Tomas I, Cabrera-Rubio R et al. Microbial geography of the oral cavity. J Dent Res 2013; 92: 616-621.
7. Morita H, Kuwahara T, Ohshima K et al. An improved DNA isolation method for metagenomic analysis of the microbial flora of the human intestine. Microbes Environ 2007; 22: 214-222.
8. Said HS, Suda W, Nakagome S et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunologic biomarkers. DNA Res 2014; 21: 15-25.
9. Igarashi M, Nagano J, Tsuda A et al. Correlation between the serum pepsinogen I level and the symptom degree in proton pump inhibitor-users administered with a probiotic. Pharmaceuticals 2014; 7: 754-764.
10. Kim S-W, Suda W, Kim S et al. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res 2013; 20: 241-253.
11. Li X-X, Wong GL-H, To K-F et al. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS ONE 2009; 4: e7985.
12. Lozupone C, Lladser ME, Knight D et al. UniFrac: an effective distance metric for microbial community comparison. ISME J 2011; 5: 169-172.
13. Wu WM, Yang YS, Peng LH. Microbiota in the stomach: new insights. J Digest Dis 2014; 15: 54-61.
14. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207-214.
15. Bik EM, Eckburg PB, Gill SR et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA 2006; 103: 732-737.
16. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134: 306-323.
17. Eun CS, Kim BK, Han DS et al. Difference in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter 2014; 19: 407-416.
18. Stockbruegger RW. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol 1985; 111: 7-16.
19. Wilder-Smith CH, Spirig C, Krech T et al. Bactericidal factors in gastric juice. Eur J Gastroenterol Hepatol 1992; 4: 885-891.
20. Amir I, Konikoff FM, Oppenheim M et al. Gastric microbiota is altered in esophagitis and Barrett's esophagus and further modified by proton pump inhibitors. Environ Microbiol 2013; 16: 2905-2914.
21. Vesper BJ, Jawdi A, Altman KW et al. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab 2009; 10: 84-89.
22. Garcia-Mazcorro JF, Suchodolski JS, Jones KR et al. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiol Ecol 2012; 80: 624-636.
23. Valera E, Manichanh C, Gallart M et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 151-161.
24. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
25. Gilbert MW, Mattia A. Collagenous colitis associated with lansoprazole. J Clin Gastroenterol 2002; 34: 164-166.
26. Seto CT, Jeraldo P, Orenstein R et al. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2014; 2: 42.